The CAR-T Paradox: Why Arcellx Shares Tumbled Despite 100% Response Rate
Lyra Therapeutics Gambles on Higher Dose in New Phase 3 Trial Following Previous Setback for Chronic Rhinosinusitis Treatment
The Uncomfortable Truth: Why Your Chronic Sinus Treatment Might Be Failing You